Sulforaphane — Research Profile

Yes, but broccoli sprouts are a far better source — containing 20-100 times more glucoraphanin than mature broccoli. Raw broccoli sprouts provide the most sulforaphane because cooking destroys the myrosinase enzyme needed for conversion. If you eat cooked broccoli, adding mustard seed powder (which contains myrosinase) can restore sulforaphane production. Supplements standardized with myrosinase offer the most consistent dosing.

Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that activates over 200 genes involved in antioxidant defense, detoxification, and inflammation control. It is your body's master switch for cellular protection. Nrf2 activity declines with age, leaving cells more vulnerable to oxidative stress. Activating Nrf2 with sulforaphane restores this protective capacity and is considered one of the most promising longevity strategies.

Most broccoli sprout supplements contain glucoraphanin, which is the inactive precursor. The myrosinase enzyme converts glucoraphanin into active sulforaphane. Without myrosinase (either from the supplement or your gut bacteria), conversion rates are only 1-40% and highly variable between individuals. Look for products that include myrosinase enzyme, or choose pre-formed stabilized sulforaphane for consistent results.

Preformed (stabilized) sulforaphane is the most bioavailable option, with about 70 to 90 percent urinary recovery, versus glucoraphanin-only extracts that depend on gut bacteria and deliver far less. Glucoraphanin combined with active myrosinase is the next best choice and is the form most broccoli-sprout trials, including the detoxication study, actually used. No head-to-head trial has crowned a single best commercial form for clinical outcomes, so bioavailability is the practical deciding factor.

The best-supported human effect is enhancing the body's detoxification of environmental pollutants: in a 291-person trial, a broccoli-sprout beverage raised urinary excretion of benzene and acrolein metabolites by roughly 61 percent and 23 percent. A small RCT reported reduced fasting glucose and HbA1c in obese type 2 diabetes, and an autism RCT showed a 34 percent improvement on the Aberrant Behavior Checklist, but a schizophrenia meta-analysis found no benefit on core symptoms or cognition. Most other proposed uses still rest on preclinical Nrf2-pathway data rather than confirmed human outcomes.

No standardized daily dose is established. Human trials have used a wide span, roughly 10 to 850 micromol of sulforaphane per day (median around 100 micromol), or 25 to 800 micromol of glucoraphanin, with no consensus optimum. Concrete anchors from major trials include 40 micromol sulforaphane plus 600 micromol glucoraphanin daily for pollutant detoxification, and 50 to 150 micromol daily in the autism study.

No study has directly compared times of day, so an optimal time has not been established. Because sulforaphane is absorbed within a couple of hours and cleared with a short half-life, and glucoraphanin needs either supplemental or gut-bacterial myrosinase to convert, taking it with food and alongside a myrosinase source is a sensible practical approach. Clinical trials simply dosed once or twice daily without specifying a time of day.

The most common complaints are gastrointestinal, chiefly nausea, heartburn, and general GI discomfort, and they become more frequent as the dose rises. Concentrated preparations can also cause a harsh, burning sensation in the throat at intakes above about 100 micromol. Serious adverse events have not been reported in controlled trials; in a 369-patient schizophrenia meta-analysis, dropout was actually lower on sulforaphane than on placebo.

No clinically significant drug interactions have been established in human sulforaphane trials. Mechanistically it activates Nrf2 and induces phase II detoxification enzymes, which is exactly how it accelerates clearance of environmental toxins like benzene and acrolein; in principle this could alter how the body processes some medications, but that has not been demonstrated clinically. Until human interaction data exist, anyone on narrow-therapeutic-index drugs should treat combined use cautiously.

The most direct human evidence favors people with high exposure to airborne pollutants, where sulforaphane boosted excretion of benzene and acrolein, and it has shown early promise in obese type 2 diabetes and in autism spectrum disorder. It is not supported for schizophrenia symptoms or cognition, and most other proposed uses remain preclinical. In every case it is an adjunct being studied, not a replacement for established treatment.

Sulforaphane is absorbed within a few hours, but how fast you see an effect depends on the outcome. In the 291-person Qidong broccoli-sprout-beverage trial, enhanced urinary excretion of benzene and acrolein pollutant metabolites appeared from day 1 and held steady across 12 weeks. Clinical and behavioral endpoints are far slower: the autism RCT dosed for 18 weeks to reach its full effect, and the gains faded within weeks of stopping.

Controlled trials have dosed sulforaphane daily for up to 18 to 24 weeks with good tolerability; the autism RCT ran 18 weeks, and a meta-analysis of four schizophrenia trials (369 patients) spanning 12 to 24 weeks found lower dropout on sulforaphane than on placebo. Beyond roughly six months there is little controlled human data, and a 2024 systematic review concluded that safe long-term human doses have not yet been firmly established.

No toxic threshold or upper limit has been defined for sulforaphane in humans, and a Phase I trial found no clinically significant changes across 32 hematology and chemistry tests, including liver and thyroid panels. That said, single doses above about 100 micromol commonly cause a harsh, burning sensation in the back of the throat, and higher intakes bring more reports of nausea, heartburn, and other gastrointestinal discomfort. Because tolerability worsens as the dose climbs without a demonstrated added benefit, there is no established rationale for megadosing.

No dangerous interactions between sulforaphane and common supplements have been documented. The one pairing that clearly changes its effect is myrosinase: taking a glucoraphanin supplement alongside an active myrosinase source (such as fresh broccoli sprouts or mustard-seed powder) raises conversion to active sulforaphane from as little as 1 to 15 percent up to roughly 20 to 35 percent. Beyond that, no supplement stack has been proven in humans to enhance sulforaphane's clinical benefits.

Focus on how much active sulforaphane the product actually delivers, not just its glucoraphanin number. Glucoraphanin only converts to sulforaphane in the presence of the enzyme myrosinase, which heat processing destroys in many extracts; without it, urinary sulforaphane recovery can be as low as 1 to 15 percent, versus 20 to 35 percent when active myrosinase is included. Choose products standardized to a stated sulforaphane yield, or ones that pair glucoraphanin with active (heat-preserved) myrosinase.